Paris, France

Catherine Iung

This inventor holds 1 USPTO granted patent. Top assignee: Societe Cooperative Agricole Laitiere D'artois Et Des Flandres, La. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Catherine Iung

Introduction

Catherine Iung is a notable inventor based in Paris, France. She has made significant strides in the field of pharmaceuticals, particularly with her innovative work involving decapeptides. Her contributions are aimed at addressing critical health issues such as convulsions and anxiety.

Latest Patents

Catherine Iung holds a patent for the "Use of a decapeptide with benzodiazepine-type activity for preparing." This invention relates to the use of a decapeptide with the amino acid sequence of SEQ ID NO.:1 in the preparation of medicines that exhibit benzodiazepine-type activity. The applications of her invention are particularly useful for treating convulsions and anxiety. Additionally, the invention encompasses pharmaceutical compositions, food supplements, and foodstuffs for special diets that contain the said decapeptide.

Career Highlights

Catherine Iung is associated with the company Société Cooperative Agricole Laitière D'Artois et des Flandres. Her work there has allowed her to focus on innovative solutions in the agricultural and pharmaceutical sectors.

Collaborations

Catherine has collaborated with notable coworkers such as Laurent Miclo and Emmanuel Perrin. Their combined expertise has contributed to the advancement of her research and inventions.

Conclusion

Catherine Iung's work exemplifies the impact of innovative thinking in the pharmaceutical industry. Her patent for a decapeptide with benzodiazepine-type activity showcases her commitment to improving health outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…